Description

With the ageing population, China has become the country with the largest number of people suffering from osteoporosis which is the most severe disease second to cardiovascular diseases. A nationwide large-scale epidemiological survey has also shown that the incidence of osteoporosis in China is 12.4% and that this figure among women aged 50 and above is 50%. It is estimated that the number of osteoporosis patients and patients with low bone mass will rise to 280 million by 2020.

View Full Report at: http://www.marketresearchreports.biz/analysis/294350

Currently, drugs for the prevention and treatment of osteoporosis are mainly categorized into bone resorption inhibitor which includes diphosphonate (alendronate, etidronate and risedronate), sex hormone, calcitonin, selective estrogen receptor modulator and bone formation promoter, fluoride product, vitamin D and calcium preparation, parathyroid hormone included.

As a member of the new generation of osteoporosis drugs, risedronate sodium is used for the treatment and prevention of osteoporosis in postmenopausal women. Risedronate sodium has brought in a large amount of sales value in the global market, for example, over USD 1 billion in 2004. According to CRI’s market survey, risedronate sodium develops fast after appearing in the Chinese market, annual sales value in sample hospitals rising from less than 40,000 in 2008 to CNY 9.71 million in 2014 and CAGR during this period reaching 156%. Risedronate sodiums in the Chinese market are all produced by local enterprises represented by Kunming Jida Pharmaceutical Co., Ltd, Topfond, Yangtze River Pharmaceutical Group, Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd and Beijing SL Pharm, among which Kunming Jida Pharmaceutical Co., Ltd has the largest market share of 84% for sales value in 2014.

Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/294350

With the ageing population, the incidence of osteoporosis will continue to grow. Therefore the market size of risedronate sodium is expected to keep expanding fast in the next few years in China.




Readers can get at least the following information from this report:

market size of risedronate sodium in China
competitive landscape of risedronate sodium in Chinese market
price of risedronate sodium made by different enterprises in China
market outlook of risedronate sodium in China

The author suggests the following groups of people purchase this report:

manufacturers of osteoporosis drugs
investors/ research institutions interested in Chinese medicine market
any interest in the Chinese medicine market, please contact CRI for customized survey service


Browse all latest Articles of Market Research Reports
at:http://www.marketresearchreports.biz/articles


About us

MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.

Browse Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz

Browse More PressRelease:
http://www.prweb.com/search.aspx?search-releases=marketresearchreports.biz


Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: [email protected]